Cardio Diagnostics (NASDAQ:CDIO) Releases Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) posted its quarterly earnings data on Friday. The company reported ($0.59) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%.

Cardio Diagnostics Stock Performance

Shares of CDIO stock remained flat at $1.68 during mid-day trading on Friday. 18,908 shares of the stock were exchanged, compared to its average volume of 23,643. Cardio Diagnostics has a 52 week low of $0.97 and a 52 week high of $7.91. The company has a market capitalization of $4.96 million, a P/E ratio of -0.57 and a beta of 2.32. The firm’s fifty day moving average is $1.84 and its 200-day moving average is $2.06.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Cardio Diagnostics presently has a consensus rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.